Gilead Sciences, Inc.

GILD

US3755581036

Gilead Sciences, Inc. specializes in the development, manufacturing and marketing of therapeutic products. Net sales break down by source of income as follows: - sale of drugs (98.9%): for the treatment of HIV (63% of net sales), COVID-19 (20.4%), hepatitis C virus (6.6%), hepatitis B virus (3.6%) and other (6.4%; primarily cytomegalovirus retinitis, and advanced Kaposi sarcoma resulting from HIV); - other (1.1%): especially royalties and revenue from research and development services and from subcontracted production of therapeutic products. Net sales are distributed geographically as follows: the United States (69.2%), Europe (16.4%) and other (14.4%).

Sector

Pharmaceuticals

Calendar

09/08/2024 - Q2 2024 Earnings Release

Related indices

S&P 500

More about the company

Income Statement Evolution

More financial data

Ratings for Gilead Sciences, Inc.

Trading Rating

Investor Rating

ESG Refinitiv

B-

More Ratings

Analysts' Consensus

Sell

Buy

Mean consensus

OUTPERFORM

Number of Analysts

Last Close Price

70.67 USD

Average target price

82.7 USD

Spread / Average Target

+17.02%

Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Other Pharmaceuticals

	1st Jan change	Capi.
GILEAD SCIENCES, INC.	-12.76%	88.04B
ELI LILLY AND COMPANY	+51.63%	796B
NOVO NORDISK A/S	+41.51%	628B
JOHNSON & JOHNSON	-5.10%	358B
MERCK & CO., INC.	+19.90%	331B
ABBVIE INC.	+9.95%	301B
ASTRAZENECA PLC	+17.66%	244B
ROCHE HOLDING AG	+3.39%	228B
NOVARTIS AG	+10.75%	214B
AMGEN INC.	+6.99%	165B

Other Pharmaceuticals

Market Closed - Nasdaq Other stock markets 01:30:00 22/06/2024 am IST			After market 04:53:02 am
70.67 ^USD	+3.18%		71.08	+0.57%

21/06	Tech overload on Wall Street
21/06	Wall Street set for muted open as investors await business survey data	RE

Tech overload on Wall Street	21/06
Wall Street set for muted open as investors await business survey data	21/06	RE
Nvidia Slide Stifles US Equity Futures Pre-Bell	21/06	MT
Top Premarket Gainers	21/06	MT
Wall Street futures edge lower ahead of business survey data	21/06	RE
Equity Markets Close Mixed as Investors Weigh Economic Data	21/06	MT
Equity Markets Close Mixed After Macro Data	21/06	MT
Health Care Stocks Rise Behind Gilead -- Health Care Roundup	21/06	DJ
US Equities Markets Close Mixed Thursday as Markets Parse Latest Economic Data	21/06	MT
Sector Update: Health Care Stocks Higher Late Afternoon	21/06	MT
Sector Update: Health Care Stocks Mixed Thursday Afternoon	20/06	MT
Equity Markets Mixed as Traders Weigh Macro Data	20/06	MT
Sliding Technology Stocks Push S&P 500, Nasdaq Composite Lower	20/06	MT
Sector Update: Health Care	20/06	MT
Gilead Sciences' Twice-Yearly Shot Prevents 100% of HIV Cases in Trial, Shares Jump	20/06	MT
US Benchmark Stock Indexes Mixed in Midday Trading	20/06	MT
Gilead Sciences' Lenacapavir Shows 100% Efficacy, Superiority to Truvada For HIV Prevention	20/06	MT
Gilead Sciences HIV Prevention Treatment Shows 100% Effectiveness in Phase 3 Trial	20/06	DJ
Gilead's long-acting HIV drug superior to daily pill Truvada in study	20/06	RE
Gilead Sciences, Inc. Announces Topline Results from an Interim Analysis of Its Pivotal, Phase 3 Purpose 1 Trial	20/06	CI
Assembly Biosciences, Inc. announced that it has received $2.77507 million in funding from Gilead Sciences, Inc.	17/06	CI
Health Care Slips as Gilead Rallies on Weight-Loss Plans - Health Care Roundup	15/06	DJ
EU regulator mandates label updates on CAR-T cancer therapies	14/06	RE
Gilead Sciences' Kite Unit Reports Positive Data From New Analyses of Yescarta	14/06	MT
Kite Announces Clinical Research and Real-World Evidence for Yescarta Demonstrate Benefit From Earlier Lines of Treatment	14/06	CI